/OVB.L

OVB.L Stock - Ovoca Bio plc

Q: What is the analyst price target for OVB.L?

Analyst price target information is not currently available for OVB.L.

Q: What is OVB.L's market cap?

Market capitalization information is not currently available for OVB.L.

Healthcare|Biotechnology|LSE

$1.15-9.80%

$0.13 (-9.80%) • May 6

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.26

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for OVB.L

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.47

52W High$1.98

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-3,000	$-5,099,000	$-5,577,000	$-5,330,000	$-2,533,000
Net Income	$-746,000	$-4,702,000	$-5,612,000	$-5,475,000	$-2,336,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$0.00	$-0.07	$-0.07	$-0.07	$-0.03

Company Overview

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Visit Website

Earnings History & Surprises

OVB.L

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.01

Q2 2019

EPS Surprise History

Q1 17

No data

Q2 17

No data

Q1 18

No data

Q1 18

No data

Q2 18

No data

Q1 19

No data

Q1 19

No data

Q2 19

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2019	Jun 30, 2019	—	$-0.01	—	—
Q1 2019	Mar 31, 2019	—	$-0.01	—	—
Q1 2019	Jan 31, 2019	—	$-0.01	—	—
Q2 2018	Jun 30, 2018	—	$-0.01	—	—
Q1 2018	Mar 31, 2018	—	$-0.01	—	—
Q1 2018	Jan 31, 2018	—	$-0.01	—	—
Q2 2017	Jun 30, 2017	—	$-0.00	—	—
Q1 2017	Mar 31, 2017	—	$-0.00	—	—
Q1 2017	Jan 31, 2017	—	$-0.00	—	—
Q2 2016	Jun 30, 2016	—	$-0.00	—	—
Q1 2016	Mar 31, 2016	—	$-0.00	—	—
Q1 2016	Jan 31, 2016	—	$-0.00	—	—
Q3 2015	Sep 30, 2015	—	$-0.01	—	—
Q2 2015	Jun 30, 2015	—	$-0.01	—	—
Q1 2015	Mar 31, 2015	—	$-0.01	—	—
Q1 2015	Jan 31, 2015	—	$-0.01	—	—
Q3 2014	Sep 30, 2014	—	$-0.02	—	—
Q2 2014	Jun 30, 2014	—	$-0.02	—	—
Q1 2014	Mar 31, 2014	—	$-0.02	—	—
Q1 2014	Jan 31, 2014	—	$-0.02	—	—